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Abstract
Solid tumors are composed of cancerous cells and non-cancerous stroma. A better understanding of the tumor stroma
could lead to new therapeutic applications. However, the exact compositions and functions of the tumor stroma are still
largely unknown. Here, using a Lewis lung carcinoma implantation mouse model, we examined the hematopoietic
compartments in tumor stroma and tumor-bearing mice. Different lineages of differentiated hematopoietic cells existed in
tumor stroma with the percentage of myeloid cells increasing and the percentage of lymphoid and erythroid cells
decreasing over time. Using bone marrow reconstitution analysis, we showed that the tumor stroma also contained
functional hematopoietic stem cells. All hematopoietic cells in the tumor stroma originated from bone marrow. In the bone
marrow and peripheral blood of tumor-bearing mice, myeloid populations increased and lymphoid and erythroid
populations decreased and numbers of hematopoietic stem cells markedly increased with time. To investigate the function
of hematopoietic cells in tumor stroma, we co-implanted various types of hematopoietic cells with cancer cells. We found
that total hematopoietic cells in the tumor stroma promoted tumor development. Furthermore, the growth of the primary
implanted Lewis lung carcinomas and their metastasis were significantly decreased in mice reconstituted with IGF type I
receptor-deficient hematopoietic stem cells, indicating that IGF signaling in the hematopoietic tumor stroma supports
tumor outgrowth. These results reveal that hematopoietic cells in the tumor stroma regulate tumor development and that
tumor progression significantly alters the host hematopoietic compartment.
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Introduction
Solid tumors are composed of cancerous and non-cancerous
cells. The non-cancerous cells, including endothelial cells, hema-
topoietic cells, fibroblasts, myofibroblasts, pericytes, and mesen-
chymal stem cells, collectively form the cancer stroma or
microenvironment [1,2]. These stromal cells come from the local
environment or from bone marrow (BM) via the circulation system
and appear to provide important support for cancer cell growth
and metastasis [1,2]. For instance, BM-derived cells are recruited
to the cancer site to stimulate outgrowth of tumors and form
angiogenic and pre-metastatic niches for cancer growth [3,4,5].
Stromal fibroblasts and mesenchymal stem cells also play critical
roles in angiogenesis and metastasis, respectively [6,7]. However,
the exact compositions and functions of the microenvironment
that surround solid cancer are still largely unknown. Since a tumor
cannot develop without the parallel expansion of a tumor stroma,
the lack of understanding of this cancer microenvironment has
severely hampered cancer research and the development of
effective therapeutic approaches.
There is ample evidence that certain differentiated hematopoi-
etic cells, including macrophages, T cells, and mast cells, are
incorporated into the tumor microenvironment [1,2]; however, a
systematic investigation of the composition of the hematopoietic
compartment of the tumor stroma has not been carried out.
Hematopoiesis in vertebrates is a hierarchically organized
developmental process in that highly specialized differentiated
cells, including progenitors, precursors, and different lineages of
blood cells, originate through an ordinate maturation program
from the primitive hematopoietic stem cells (HSCs) [8]. Of these
cells, HSCs are defined by their ability to self-renew and to
differentiate into all blood cell types, whereas various progenitors
posses much more limited self-renewal capacity and differentiation
potential. In adults, HSCs mainly reside in BM; a small fraction
also circulate in the blood stream and can be found in
extramedullary organs including spleen and liver [8,9]. The flow
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assays, including the BM reconstitution analysis, remain the assays
of choice for the analysis of the presence and activities of various
hematopoietic cell types [8].
We sought to determine the composition and function of
hematopoietic cells in tumor stroma and to determine whether
tumor development affects the hematopoietic compartment of a
tumor-bearing host. These studies are of fundamental importance
to our understanding of the basic molecular and cellular
mechanisms of tumor pathogenesis. A more complete understand-
ing of the tumor microenvironment will make possible novel types
of anti-tumor therapy.
Results
Various hematopoietic populations exist in tumor stroma
Using the Lewis lung carcinoma (LL2) implantation mouse
model, we characterized the hematopoietic compartment in the
tumor stroma. Figures 1A–C and Table 1 show the results of
staining for hematopoietic cell surface antigens in dissociated
tumor masses arising after the subcutaneous injection of 10
6 LL2
cells into C57BL/6 CD45.1 host mice at various time points post-
implantation. The composition of hematopoietic cells in tumor
stroma differed from that from host peripheral blood (PB) or BM
(Table 1), indicating that there exists a unique hematopoietic
Figure 1. Analysis of the hematopoietic compartment of LL2 tumor stroma. Fig. 1A–C show the results of flow cytometry staining for
hematopoietic cell surface antigens in dissociated tumor masses arising after the subcutaneous injection of 10
6 LL2 cells into C57BL/6 CD45.1 host
mice at indicated days post-implantation. (A) Flow cytometry analysis of hematopoietic cells and their major lineages in LL2 tumor stroma at day 12,
15, and 19 after implantation as total hematopoietic cells (CD45), T cells (Thy1.2), B cells (B220), myeloid cells (Mac-1 and Gr-1), and erythroid cells
(Ter119
+) (n=5). * significantly different from day 12 values. (B) Representative flow cytometry plots showing that CD45
+Lin
2Sca-1
+Kit
+ (LSK) cells
exist in LL2 tumor stroma. (C) Frequencies of CD45
+Lin
2Sca-1
+Kit
+ cells in LL2 tumor stroma at day 12, 15, and 19 after implantation (n=5).
* significantly different from day 12 values. (D) HSCs in the LL2 tumor stroma have long-term repopulation ability and repopulate secondary
recipients. Lethally irradiated CD45.2 congenic mice were injected with 1610
5 CD45.2 bone marrow competitor cells and 1610
6 CD45.1 cells, isolated
from the LL2 tumor mass. Shown are the repopulation activities of hematopoietic populations derived from the cancer stroma in long-term
reconstitution (n=6) and secondary reconstitution experiments (n=5). (E–F) Donor repopulation in T lineage (CD3), B lineage (B220), and myeloid
lineage (Mac-1/Gr-1) in peripheral blood in the experiment described in panel D at 7 months post-transplant (n=6). (G) Hematopoietic cells in tumor
stroma originate from host BM. 1,000,000 CD45.1 donor BM cells were transplanted into lethally irradiated CD45.2 C57BL/6 mice. At 4 months post-
transplant, 10
5 LL2 tumor cells were subcutaneously implanted into these mice. Three weeks later, flow cytometry was used to characterize the
hematopoietic cells in tumor stroma. A representative flow cytometry plot shows 100% of the tumor stromal CD45
+ cells were CD45.1
+.
doi:10.1371/journal.pone.0018054.g001
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cells in the LL2 tumor stroma modestly increased from 20.6% at
day 12 to 25.3% at day 19 after tumor implantation (Fig. 1A). The
relative composition of myeloid cells (Mac-1
+ and Gr-1
+) increased
whereas that of lymphoid cells (T cells as Thy1.2
+ and B cells as
B220
+) and erythroid cells (Ter119
+) in this compartment
decreased over time (Fig. 1A).
We also measured the existence of hematopoietic progenitors
and phenotypic HSCs in the tumor stroma. The number of
progenitors for granulocytes and monocytes (CFU-GM) was low,
with 3.5 per 1,000,000 tumor cells at day 19 post-implantation
(Table 1). Interestingly, in the LL2 tumor stroma, we found
phenotypic HSCs, measured as CD45
+Lin
2Sca-1
+Kit
+ cells
(Fig. 1B). The flow cytometry analyses indicate that there were
few Lin
2Kit
+ cells in the tumor stroma, concordant with a
previous report [3]. The average frequency of these phenotypic
HSCs increased over time from 0.0004% at day 12, to 0.0016% at
day 15, and to 0.006% at day 19 (Fig. 1C). In particular, the
frequency of phenotypic HSCs detected in the tumor stroma
(0.00660.001%) at day 19 was 1/13 or 1/33 of that in BM of
normal mice or tumor-bearing mice respectively (0.0860.05 and
0.2060.02% respectively) (Table 1). Since the tumors were
perfused, and the cell composition including the percentage of
HSCs in tumor stroma was quite different from that in peripheral
blood, our result indicates that phenotypic HSCs reside in tumor
stroma and are not contaminant from blood.
Since the surface phenotype of HSCs in extramedullary organs
can be different from that of BM HSCs [9], we used BM
reconstitution analysis, the ‘‘gold standard’’ for measuring HSC
repopulating activity, to determine whether functional HSCs
existed in the tumor stroma. As we performed before [10,11,12,
13,14,15,16], we examined the HSC activity of the donor cells in
competitive reconstitution analyses, in which lethally irradiated
recipient mice were co-transplanted with both the donor cells to be
tested and WT BM competitors. The competitor cells serve as an
internal control and as a supply of hematopoietic cells until the
transplanted stem cells can generate sufficient mature lymphoid
and myeloid cells for survival. Donor and recipient mice are
genetically identical except for the CD45 surface protein that is
found on nucleated peripheral blood cells and that is not involved
in hematopoiesis or stem cell activity; donor cells carried the
marker CD45.1, while recipient mice and supportive cells
expressed CD45.2. An extremely stringent 18-month competitive
reconstitution analysis and a secondary transplantation showed
that the tumor stroma contained long-term repopulating HSCs
(Fig. 1D). These cells were capable of repopulating both lymphoid
and myeloid lineages in long-term reconstitution analysis (Fig. 1E–
F), attesting that these are functional HSCs. The relative low
repopulation of the donor cells in all lineages compared to BM
competitors suggests these HSCs in the tumor stroma have weak
engraftment to the recipient BM. Nevertheless, our data, for the
first time to our knowledge, demonstrated that functional HSCs
exist in tumor stroma.
To determine whether the hematopoietic cells in tumor stroma
originated from the BM or from the local environment, we
transplanted CD45.1 C57BL/6 donor BM cells into lethally
irradiated CD45.2 C57BL/6 mice. At 4 months post-transplant,
the recipient BM was completely repopulated by the donor
CD45.1 cells, whereas peripheral tissues contained mostly CD45.1
cells with certain CD45.2 cells as reported [9]. We implanted LL2
tumor cells subcutaneously into these mice. Three weeks later, we
isolated tumors and used flow cytometry to characterize the
hematopoietic cells in stroma. We found that all of the tumor
stromal CD45
+ cells were CD45.1
+ (Fig. 1G). Accordant with
previous studies [3], we concluded that hematopoietic cells in the
LL2 stroma are derived from BM.
HSC numbers dramatically increase in tumor-bearing
mice
Next we sought to determine whether the host hematopoietic
compartment was affected by tumor growth. Total cellularity and
total hemtopoietic cell counts of tumor-bearing mice did not
significantly change over time (Fig. 2A–B). However, in both BM
and PB of tumor-bearing mice we observed significantly increased
percentages of myeloid (Mac-1
+ and Gr-1
+) cells but decreased
lymphoid (Thy1.2
+ and B220
+) and erythroid (Ter119
+) cells as a
function of time post-implantation (Fig. 2C–D). This trend is
similar to what occurred in the hematopoietic lineages in tumor
stroma. In addition, we analyzed the frequencies and numbers of
hematopoietic progenitors and phenotypic HSCs in the tumor-
bearing mice and healthy controls. CFU-GM increased approx-
imately 2-fold whereas CFU-E and CFU-Pre-B decreased at least
50% in tumor-bearing mice compared to normal mice (Fig. 2E),
concordant with the total increase of myeloid cells and decrease of
Table 1. Repopulating hematopoietic stem cells and differentiated hematopoietic cells exist in LL2 tumor stroma.
1 245 6 7 89 1 0
CD45
+ % Thy1.2
+ % B220
+ % Mac-1
+ % Gr-1
+ % Ter119
+ %
CFU-GM (per 1
million cells)
CD45
+Lin
2
Sca-1
+Kit
+ %
Tumor stroma 25.362.8 1.360.1 4.860.4 19.761.6 12.160.9 0.360.1 3.560.5 0.00660.001
Tumor peripheral
blood
98.762.4 11.761.9 13.162.2 74.563.7 66.464.5 15.065.6 N/D 0.00960.002
Tumor bone
marrow
77.062.0 0.960.2 5.562.5 70.563.8 61.164.7 19.464.2 2962682 0.260.02
Normal peripheral
blood
99.362.2 30.769.7 39.562.7 26.5612.2 19.3610.7 28.963.6 N/D 0.000960.0005
Normal bone
marrow
69.762.9 2.860.2 20.761.3 44.064.4 41.564.9 32.562.5 1425632 0.0860.05
Normal muscle 1.660.2 0.860.1 0.160.01 0.260.01 0.560.04 0.160.01 060 0.060.0
Data from tumor mice were obtained from dissociated tumor masses arising after the subcutaneous injection of 10
6 LL2 cells into C57BL/6 CD45.1 host mice at day 19
post-implantation (n=5).
doi:10.1371/journal.pone.0018054.t001
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typic HSCs as Lin
2Sca-1
+Kit
+CD34
2Flk-2
2 or Lin
2Sca-1
+Kit
+
cells increased over time. Numbers of BM HSCs increased about
3-fold and PB HSCs increased 7-fold at day 19 relative to numbers
on day 12 (Fig. 2F–G). This suggests that the presence of a tumor
induces in vivo expansion of HSCs and progenitors in the BM,
which leads to increased HSCs and progenitors in the circulation.
Consistent with this result, the tumor-bearing mice display
splenomegaly, with 2-fold increase of spleen size and weight
compared to healthy controls (data not shown).
Because numbers of HSCs in the tumor-bearing mice signi-
ficantly increased, we tested whether the cell cycle of HSCs in the
host BM changed. As shown in Figure 2H, there was no significant
changes in fractions of cells in given cell cycle stages in HSCs in
the BM of tumor-bearing mice at day 19 compared to normal
mice, suggesting that the tumor did not significantly alter the
quiescence of host BM HSCs at the late stage of cancer
development.
Co-implanted hematopoietic cells from tumor stroma
promote tumor development
We developed an assay to compare the abilities of different
hematopoietic populations to collaborate functionally with tumor
cells to affect the tumor development. In this assay, we use FACS
to isolate a certain population of hematopoietic cells and mix them
with a fixed number of LL2 cancer cells prior to implantation into
the C57BL/6 mice. The kinetics of tumor growth was determined
to evaluate the tumor-promoting ability of the co-implanted
hematopoietic cells. In the experiment summarized in Figure 3A,
we co-implanted 1610
5 LL2 cells with 1610
4 CD45.1 total BM
cells or with enriched normal BM HSCs as Lin
2Sca-1
+Kit
+ cells
subcutaneously into C57BL/5 CD45.2 host mice. During the 3-
Figure 2. Analysis of the hematopoietic compartment of the LL2 tumor-bearing mice. (A–G) Total BM cells (A), total hematopoietic cells in
BM (B), hematopoietic lineages in BM (C), hematopoietic lineages in PB (D), hematopoietic progenitors in BM (E), CD45
+Lin
2Sca-1
+Kit
+CD34
2FLK2
2
cells in BM (F), and CD45
+Lin
2Sca-1
+Kit
+cells in PB (G) at indicated days in C57BL/6 CD45.1 host mice before and after the subcutaneous injection of
10
5 LL2 cells were analyzed by flow cytometry or colony assays (n=5). * significantly different from day 0 or normal values (for panel B–E), or from day
12 values (for panel F–G). (H) The cell cycle status of BM HSCs in tumor-bearing mice at day 19 post-implantation does not significantly differ from
that of counterparts in normal mice. HSCs as Lin
2Sca-1
+Kit
+Flk2
2CD34
2 cells were stained with Hoechst 33342 and pyronin Y, and analyzed for cell
cycle stage (n=5).
doi:10.1371/journal.pone.0018054.g002
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show that both total BM cells and the enriched HSC population
positively regulated tumor growth. It is noteworthy that the co-
implantation of total BM cells with LL2 cells led to similar level of
tumor size as the same number of transplanted LSK cells. Clearly,
differentiated hematopoietic cells did promote tumor progression.
This suggests that additional HSCs in the tumor local environment
do not necessarily further promote tumor growth.
We further determined the effect of hematopoietic cells isolated
from the tumor stroma on cancer development. Because it was
technically difficult to isolate the low frequent Lin
2Sca-1
+Kit
+ cells
from these tumors, we isolated hematopoietic cells from LL2
tumor stroma or host PB as a control and co-injected them with
GFP
+LL2 tumor cells into secondary mice. We found that,
although the host PB CD45
+ cells stimulated LL2 tumor growth
compared to LL2 cells alone, CD45
+ cells isolated from previously
existing tumor stroma had significantly increased ability to
enhance LL2 tumor growth than these PB CD45
+ cells (Fig. 3B,
p,0.05). This result suggests that 1) hematopoietic cells in tumor
stroma enhance tumor growth, 2) hematopoietic cells from tumor
stroma are different from those from PB in promoting tumor
growth, not unexpectedly as the compositions of these two sources
of cells are different (Table 1), and 3) tumor stroma has certain
‘‘educating’’ effect on hematopoietic cells that leads to tumor
development.
IGF-IR expressed on cells from hematopoietic stroma is
important for tumor development and metastasis
To further validate the pathological effect of the hematopoietic
cells in the tumor stroma, we studied the role of IGF signaling in
these hematopoietic compartment. We previously showed that the
the receptor for IGF-2 is expressed on the surface of all HSCs [10].
IGF type I receptor (IGF-IR) is the signaling receptor for insulin-
like growth factor 1 and 2 (IGF-1 and IGF-2). The IGF pathway
has been reported to play important roles in the development of a
range of malignancies, including both non-small cell lung cancer
and small cell lung cancer (see review [17]). For example, elevated
plasma levels of IGF-1 and single nucleotide polymorphisms
within the IGF axis are associated with an increased risk of lung
cancer [17]. The activation of IGF-IR facilitates malignant
transformation and the majority of IGF-2 transgenic mice develop
lung cancer by 18 months of age [17]. Of note is that these studies
were focused on the activity of IGF-IR that is expressed on cancer
cells. We sought to test whether IGF-IR expressed by the
hematopoietic stroma plays any role in the development of the
LL2 tumors.
Figure 3. Tumor stromal hematopoietic cells stimulate LL2 tumor growth. (A) Co-implanted HSCs or total BM cells stimulate the growth of
primary LL2 tumor. 100,000 GFP-marked LL2 cells were co-implanted with with 1610
4 CD45.1 total BM cells or enriched normal bone marrow HSCs
(as Lin
2Sca-1
+Kit
+ cells) subcutaneously into C57BL/6 CD45.2 host mice (n=8). During the 3-week period of analysis, the size of the primary tumor
was measured. (B) Tumor stromal hematopoietic cells stimulate tumor growth. 100,000 tumor stromal CD45
+ cells or PB cells from tumor-bearing
mice were collected by FACS and co-implant with 10
5 LL2 cells into healthy mice (n=5). Shown are the sizes of the primary tumors. Tumor growth
curves for different experimental groups were compared using the Generalized Estimating Equations (GEE) method with AR(1) correlation structure.
* significantly different from LL2-GFP growth curve, ** significantly different from LL2-GFP and LL2/PB CD45
+ growth curves, p,0.05.
doi:10.1371/journal.pone.0018054.g003
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2/2 mice die after birth [18,19], we were able
to collect IGF-IR
2/2 HSCs from the fetal liver. Then we
reconstituted recipient mice with IGF-IR
2/2 or wild-type fetal
liver HSCs. Four months later, the recipients were fully
repopulated by the donor IGF-IR
2/2 or wild-type HSCs, and
we implanted LL2 cancer cells into these mice. The IGF-IR
2/2
HSCs had no apparent defect in engrafting the recipient mice
(Fig. 4A), nor did they have a noticeable skew in lineage
differentiation compared to HSCs from wild-type mice (Fig. 4B).
Nevertheless, LL2 tumors grew significantly more slowly in these
IGF-IR
2/2 HSC reconstituted mice than in mice engrafted with
wild-type HSCs (Fig. 4C, p,0.05), accompanying with dramat-
ically decreased metastasis to the lung (Fig. 4D). This experiment
suggests that the lack of IGF signaling in the hematopoietic
compartment of tumor stroma hampers the solid tumor develop-
ment. This novel result complements the conventional view that
IGF signaling in tumor cells per se is important for cancer
development.
Discussion
Since cancer pathogenesis involves a concerted interplay
between the tumor and the microenvironment, it is desirable to
elucidate the roles of tumor stroma in tumor development. In this
study, we sought to determine the composition and potential
function of hematopoietic cells in the stroma of solid tumors and in
tumor-bearing mice. To this end, we used an LL2 implantation
tumor model. Cells of the LL2 line are advantageous because they
produce tumors in syngeneic C57BL/6 mice, which are ideal for
quantitating HSCs by reconstitution analysis based on congenic
CD45.1 and CD45.2 markers. Because LL2 cells are syngeneic
with their hosts, their tumorigenicity can proceed in the presence
of a fully competent host immune system. This is especially
important in a study of the hematopoietic compartment of the
tumor stroma and the tumor-bearing host. Moreover, LL2 cells,
when injected subcutaneously, can form lung metastases. This
makes it possible to compare the effects of different stromal
components on regulation of potential tumor cell migration.
Here we provide evidence that functional hematopoietic pro-
genitors and HSCs exist in tumor stroma. Although the very low
frequency of HSCs in tumor stroma makes them impossible to
observe by immunohistochemistry, we were able to detect these
cells using flow cytometry analysis and the ‘‘gold standard’’ BM
reconstitution assay. To our knowledge, this was the first
demonstration that functional HSCs exist in tumor stroma. It is
apparent that these tumor stromal HSCs are not contaminants
from PB: this was assured by our approach to isolate hematopoi-
etic cells from perfused tumors and was also attested by the
demonstration of different frequencies of various hematopoietic
populations in tumor stroma and PB. Nevertheless, these tumor
stromal hematopoietic cells do originate from BM and may be
recruited to tumor sites from PB through inflammatory signals.
Our result is supported by the emerging evidence showing that
HSCs or progenitors can themselves home to sites of inflammation
Figure 4. Mice with the IGF-IR
2/2 tumor stromal HSCs had slower tumor development in the LL2 implantation model than mice
reconstituted with wild-type HSCs. (A) C57BL/6 CD45.2 E15.5 IGF-IR
2/2 fetal liver HSCs had similar engraftment as wild-type HSCs in CD45.1
recipient mice in a competitive repopulation analysis at 4 months post-transplant (n=7). CD45.1 total BM cells were used as competitors. (B) IGF-IR
2/2
HSCs had similar differentiation into T, B, and myeloid lineages as wild-type HSCs at 4 month post-transplant (n=7). (C) Mice with the IGF-IR
2/2 tumor
stromalHSCshadslowertumorgrowthintheLL2implantationmodel.Shownisarepresentativeresultofthreeindependentexperimentsoftumorgrowth
measuredafter 1610
6 LL2cellswere implanted subcutaneouslyintoIGF-IR
2/2 or wild-type HSCs reconstitutedmice at4 monthpost-transplant (n=5). *
significantlydifferentfromtheKOgrowthcurve,p,0.05.(D)MicewiththeIGF-IR
2/2tumorstromalHSCshaddramaticallydecreasedGFP
+LL2tumorcell
metastasis in lung compared to those reconstituted with wild-type HSCs. Results shown were from pooled data from three experiments (in each
experiment n=3–5). Tumor growth curves for different experimental groups were compared using the Generalized Estimating Equations (GEE) method
with AR(1) correlation structure. * significantly different from wild-type value, p,0.05.
doi:10.1371/journal.pone.0018054.g004
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[20]. Concordant with the idea that tumors release certain
endocrine signals that change the representation of stem cells or
progenitors in other tissues or organs [3], we showed that the
tumor-bearing mice had 3-fold and 7-fold increases in of BM and
PB HSCs, respectively. Similarly, during tumor development, the
percentage of faster proliferating myeloid cells (including myeloid
progenitors) increased and that of slower growing lymphoid cells
decreased over time in host BM and PB. In summary, the whole
process appears to be as follows. Tumor-produced hormone
signals reach BM, thus BM HSCs increase. The increased
proliferation of BM HSCs exceeds the capacity of HSC microen-
vironment leading to HSC mobilization and increases in numbers
of PB HSCs. These BM-derived hematopoietic cells including
HSCs are eventually recruited to tumor and become the source of
hematopoietic cells in tumor stroma. A better understanding of the
alteration of the hematopoietic compartment in host and tumor
stroma during tumor progression may lead to new strategies for
cancer treatment. For instance, the effective retention of BM
HSCs in their BM niche or block of the migration of BM-derived
hematopoietic cells in cancer patients should negatively control the
cancer development.
Is the existence of non-cancerous cells in tumor stroma a
consequence or a cause of tumor development? So far numerous
lines of prior evidence already indicate that stromal cells play
important roles in tumor progression. Endothelial cells recruited to
the tumor mass support neovascularization. BM-derived cells have
been shown to support tumor outgrowth and form pre-metastatic
niches [3,4,5]. Stromal fibroblasts and mesenchymal stem cells
also support in angiogenesis and metastasis, respectively [6,7]. Our
studies provide further evidence that tumor stromal hematopoietic
cells regulate the tumor growth and metastasis. We found that the
co-implantation of normal HSCs with cancer cells in this tumor
model promoted tumor growth. Since total BM cells had similar
ability to stimulate co-implanted tumor growth as LSK cells,
HSCs may not directly affect tumor growth; instead, it may be
hematopoietic cells that differentiate in the tumor microenviron-
ment that play a critical role in tumor outgrowth. Nevertheless, it
seems that a combination of multiple lineages of hematopoietic
cells instead of a certain single lineage is advantageous to
promoting tumor development. When we co-implanted individual
lineage cells such as CD3
+ (T cells), B220
+ (B cells), Mac-1
+
(monocytes), Gr-1
+ (granulocytes), or Ter119
+ cells (red blood
cells) with LL2 cells, we found their tumor-promoting effects were
not as potent as LSK cells or total BM cells (data not shown). This
suggests that the full lineage spectrum that is derived from HSCs
locally may have the strongest activity in tumor promotion.
Consistent with this view, we showed that previously ‘‘educated’’
tumor stromal total hematopoietic cells had greater ability to
support tumor growth than circulating hematopoietic cells.
The IGF ligands IGF-1 and IGF-2 bind to their common
signaling receptor IGF-IR and initiate a variety of signaling events.
It is known that IGF-IR regulates cell growth, survival, adhesion,
and motility [17]. Our previous work demonstrated that all normal
HSCs express the receptor for IGF-2 and that IGF-2 stimulates ex
vivo expansion of these normal HSCs [10]. In the present study, we
found that tumor stromal HSCs are originally derived from BM.
Although IGF-IR
2/2 HSCs do not appear to have overt defects in
hematopoietic engraftment and differentiation, the incorporation of
IGF-IR
2/2 hematopoietic cells into the tumor stroma significantly
hampered tumor growth and metastasis. This suggests that IGF-IR
may regulate certain cell fates (division, differentiation, migration,
or apoptosis) or activities (such as immune response) of hematopoi-
etic cells under inflammation stress in the unique tumor stromal
environment. Overall our results reveal that, in addition to its direct
role in cancer survival and growth, IGF signaling in tumor stroma is
also important for solid cancer development. These results do not
contradict but rather complement the conventional view that IGF
signaling is important for cancer development.
Questions regarding the repopulating hematopoietic cells in
tumor stroma still remain. For example, what is the mechanism for
LL2 stroma to maintain the primitive status of a small fraction of
HSCs? One possibility is that HSCs are supported by the growth
factors, cytokines, chemokines, or membrane proteins produced by
the tumor stromal environment. As we previously demonstrated,
certain tumor cells can secrete proteins to support HSCs ex vivo [14].
It is therefore reasonable to assume that, while the LL2 stromal
environment largely supports HSC differentiation in vivo, it possesses
a certain capacity to maintain a very small number of primitive
HSCs possibly for its own sake. A systematic study of the effects of
the tumor stroma-produced factors on cell fates of HSCs will be
necessary to find the answer. Another question is, what is the exact
phenotype of HSCs in tumor stroma? Is it the same as that of BM
HSCs? We need to emphasize that, although we identified the
existence of CD45
+Lin
2Sca-1
+Kit
+ cells (as the phenotype of
enriched BM HSCs) in the LL2 stroma, we are uncertain if this
represents the actual phenotype of these HSCs. That is why we used
the ‘‘gold standard’’ reconstitution analysis to confirm the existence
of functional repopulating HSCs in this study. Given the fact that
HSCs change their surface phenotype in stressed conditions,
culture, or extramedullary tissue such as in the liver [9,11], future
investigations coupling FACS-based cell fractionation with BM
reconstitution analysis will be needed to clarify this issue. Other
questions include, whether our observation of hematopoietic
compartments in the LL2 tumor stroma can be applied to other
tumor models, metastatic cancers, and even human cancers. Since
one of the key features of hematopoietic cells is their ability to
migrate and access to various tissues and organs, we hypothesize
that this ability may contribute to the formation of clusters of
hematopoietic cells that have been ‘‘educated’’ by the primary
tumor to serve as metastatic microenvironment in distant locations.
It thus will be interesting to study the relationship between
hematopoietic cells in the primary cancer and the stroma of the
metastatic cancer. It will also be important to determine the
hematopoietic compositions of human tumor stroma.
Materials and Methods
Ethics Statement
All animal experiments were performed with the approval of UT
Southwestern Committee on Animal Care (APN# 2007-0068).
Cell lines, animals, and tumor implantation and
measurement
Murine Lewis lung carcinoma (LL2) cells were obtained from
the ATCC and cultured under standard conditions. Retroviral
MSCV-GFP was introduced into LL2 cells to produce stable
GFP
+ LL2 cells. C57BL/6 CD45.2 and CD45.1 mice were
purchased from the Jackson Laboratory or the National Cancer
Institute. IGF-IR
2/+ mice as previously described [19] were in
pure C57BL/6 background. All animals were maintained at the
University of Texas Southwestern Medical Center animal facility
and animal experiments were performed with the approval of UT
Southwestern Committee on Animal Care. Tumor cells were
injected subcutaneously into mice and mice were maintained for
about 3 weeks. Tumor size was measured on the flanks of live mice
using calipers; volume was calculated as (length of tumor)6(width
of tumor)
2/2. To analyze lung metastasis, entire lungs were
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treatment. GFP
+ LL2 cells originating from the distant implanted
tumor were counted by flow cytometry analysis. The flow
cytometry result was confirmed by counting GFP
+ surface foci of
the harvested lung under a dissecting microscope.
Preparation of hematopoietic cells from tumors
Mice were perfused with cold PBS and primary tumors were
removed and chopped with a McIlwain Tissue Chopper (Mickle
Laboratory Engineering Company). The tissue was washed with
PBS and then placed in collagenase-dispase medium (Liver Digest
Medium, Invitrogen) at 37uC for 90 min as we described
previously [21]. Cells passed through a 70-mm strainer were used
for further flow cytometry analysis or sorting.
Flow cytometry
BMandPBcellswereisolatedfrom5–8weekoldC57BL/6mice.
Lin
2Sca-1
+Kit
+ or Lin
2Sca-1
+Kit
+CD34
2Flk-2
2 cells were isolat-
ed by staining with a biotinylated lineage cocktail (anti-CD3, anti-
CD5, anti-B220, anti-Mac-1, anti-Gr-1, anti-Ter119, and anti-7-4;
Stem Cell Technologies) followed by streptavidin-PE/Cy5.5, anti-
Sca-1-FITC, and anti-Kit-APC, and anti-CD34-PE and anti-Flk-2-
PE if necessary. To analyze hematopoietic lineages and repopula-
tion of mouse HSCs, mouse peripheral blood cells were collected by
retro-orbital bleeding, followed by lysis of red blood cells and
staining with anti-CD45.2-FITC, and anti-CD45.1-PE, and anti-
Thy1.2-PE (for T-lymphoid lineage), anti-B220-PE (for B-lymphoid
lineage), anti-Mac-1-PE, anti-Gr-1-PE (cells co-staining with anti-
Mac-1 and anti-Gr-1 were deemed to be of the myeloid lineage), or
anti-Ter119-PE (for erythroid lineage) monoclonal antibodies. All
antibodies were from BD Pharmingen. The ‘‘percent reconstitu-
tion’’ shown in figures was based on the staining results of anti-
CD45.2 and anti-CD45.1. In all cases flow cytometry analysis of
hematopoietic lineages was also performed to confirm multilineage
reconstitution as we described [14,15,16].
Hematopoietic colony assays
CD45
+ cells from LL2 tumor stroma or normal BM cells were
resuspended in IMDM with 2% FBS and were then seeded into
methylcellulose medium M3334(StemCellTechnologies) for CFU-E,
M3434 (StemCell Technologies) for CFU-GM, or M3630 (StemCell
Technologies)forCFU-Pre-B assays,accordingtothemanufacturer’s
protocols and as described [16].
HSC cell cycle analysis
The cell cycle analysis with Hoechst and pyronin Y staining was
performed as described [16]. Briefly, the Lin
2Sca-
1
+Kit
+Flk2
2CD34
2 cells were collected in Hank’s buffered salt
solution medium containing 10% FBS, 1 g/liter glucose, and
20 mM Hepes (pH 7.2). Cells were washed, Hoechst 33342
(20 mg/ml, Invitrogen) was added, and cells were incubated at
37uC for 45 min after which pyronin Y (1 mg/ml, Sigma) was
added. Cells were incubated for another 15 min at 37uC, washed,
and resuspended in cold PBS. Samples were immediately analyzed
by flow cytometry (BD Biosciences, FACSAria).
Competitive reconstitution analysis
The indicated numbers of mouse CD45.2 or CD45.1 donor
cells were mixed with 1 or 2610
5 freshly isolated CD45.1 or
CD45.2 competitor BM cells, and the mixture were injected
intravenously via the retro-orbital route into each of a group of 6–9
week old CD45.1 or CD45.2 mice previously irradiated with a
total dose of 10 Gy. For secondary transplantation, CD45.1
+ cells
were collected from primary recipients and 10
6 cells were injected
with 10
5 CD45.2 competitors into lethally irradiated secondary
recipient mice. To measure reconstitution of transplanted mice,
peripheral blood was collected at the indicated times post-
transplant and the presence of CD45.1
+ and CD45.2
+ cells in
lymphoid and myeloid compartments were measured [14,16].
Statistical analysis
Data are expressed as mean 6 SEM. Tumor growth curves for
different experimental groups were compared using the Generalized
Estimating Equations (GEE) method with AR(1) correlation
structure. Tumor sizes among different experimental groups were
also compared at each time points using t-test. SAS 9.1.3 was used for
the analysis. Data were considered statistically significant if p,0.05.
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